Serpik Vjacheslav Gennadievich

Serpik V.G., Yagudina R.I. 399

Abstract: We provided a pharmacoeconomic evaluation of the treatment of gastric cancer in the second line of therapy with ramucirumab, using the relative value analysis method. Ramucirumab is the only anti-angiogenic drug registered for the treatment of advanced gastric cancer. In comparison with the standard regimens of the second line of chemotherapy for gastric cancer, the use of the ramucirumab has a statistically significant advantage, increasing the median overall survival by 30%. Ramucirumab (Cyramza) cost of treating per one patient is 1 761 564 RUB. From the perspective of relative value analysis the cost of an additional unit of effectiveness of ramucirumab is comparable or even lower than the same criteria of other antitumor drugs of monoclonal antibodies already included in the national EDL. Consequently, ramucirumab can be characterized as an acceptable technology. The budget impact analysis showed that providing patients with advanced gastric cancer with the ramucirumab is characterized by a lower burden on the drug support budget for oncological patients than bevacizumab, trastuzumab and cetuximab in the therapy of the oncology nosologies, at the their approval date. According to the results of the budget impact analysis on the drug supply of ramucirumab, 200 patients will additionally require 329.19 million rubles, which is only 0.64% of the budget for the treatment of cancer in 2016. Key words: gastric cancer, pharmacoeconomics, cost-effectiveness analysis, budget impact analysis, relative value analysis, bevacizumab, cetuximab, ramucirumab, trastuzumab.

Kulikov A.Y., Protsenko M.V., Serpik V.G. 33

The article presents updated and advanced results of a pharmacoeconomic study conducted in 2016 on the treatment of patients with pulmonary arterial hypertension II and III functional classes with ambrisentan and bosentan preparations in Russia. The evaluation was provided through cost analysis, “cost minimization” analysis, “cost-utility” analysis, “budget impact” analysis. Еhe cost of pharmacotherapy with Volibrys (ambrisentan) of arterial pulmonary hypertension, regardless of the functional class, was 1 200 000 rubles. and 1 300 000 rubles. respectively, with the need for 12 and 13 packs of the drug per year. The average annual cost of treatment with bosentan ranges from 1 368 900 rubles. up to 1 471 644 rubles. respectively, with the need for 13 and 14 packs of the drug. The results of the “cost minimization” analysis, carried out on the assumption of equal effectiveness of ambrisentan and bosentan, showed that per one patient for one year, the preparation of Volibris (ambrisentan) in comparison with the preparations of bosentan (Traklir and Bozeneks) 175 760 to 178 504 rubles. The values of the “cost-utility” coefficient for ambrisentan in the treatment of pulmonary arterial hypertension II and III of the functional class varied depending on the dosage (5 or 10 mg) from 1,831,563 rubles. up to 2 012 040 rubles for QALY and 2 667 711 rubles up to 2 787 728 rubles. for QALY. At the same time, similar averaged values for bosentan amounted to 2 480 073 rubles and 3 271 174 rubles for QALY for II and III functional class pulmonary arterial hypertension, respectively. The “budget impact” analysis based on the estimated number of patients with pulmonary arterial hypertension in the Russian Federation, which is 2936 people, showed that the transfer of this number of patients treated with the bosentan in the form of original (Tracler) and reproduced (Bozeneks) 1: 1, for treatment with the drug ambrisentan (Volibris), will allow for 2 years to save 853.2 million rubles, which is 9.7% of the budget required for the treatment of bosentan.

1 | 2
Serpik V.G., Yagudina R.I. 399

Abstract: We provided a pharmacoeconomic evaluation of the treatment of gastric cancer in the second line of therapy with ramucirumab, using the relative value analysis method. Ramucirumab is the only anti-angiogenic drug registered for the treatment of advanced gastric cancer. In comparison with the standard regimens of the second line of chemotherapy for gastric cancer, the use of the ramucirumab has a statistically significant advantage, increasing the median overall survival by 30%. Ramucirumab (Cyramza) cost of treating per one patient is 1 761 564 RUB. From the perspective of relative value analysis the cost of an additional unit of effectiveness of ramucirumab is comparable or even lower than the same criteria of other antitumor drugs of monoclonal antibodies already included in the national EDL. Consequently, ramucirumab can be characterized as an acceptable technology. The budget impact analysis showed that providing patients with advanced gastric cancer with the ramucirumab is characterized by a lower burden on the drug support budget for oncological patients than bevacizumab, trastuzumab and cetuximab in the therapy of the oncology nosologies, at the their approval date. According to the results of the budget impact analysis on the drug supply of ramucirumab, 200 patients will additionally require 329.19 million rubles, which is only 0.64% of the budget for the treatment of cancer in 2016. Key words: gastric cancer, pharmacoeconomics, cost-effectiveness analysis, budget impact analysis, relative value analysis, bevacizumab, cetuximab, ramucirumab, trastuzumab.

Kulikov A.Y., Protsenko M.V., Serpik V.G. 33

The article presents updated and advanced results of a pharmacoeconomic study conducted in 2016 on the treatment of patients with pulmonary arterial hypertension II and III functional classes with ambrisentan and bosentan preparations in Russia. The evaluation was provided through cost analysis, “cost minimization” analysis, “cost-utility” analysis, “budget impact” analysis. Еhe cost of pharmacotherapy with Volibrys (ambrisentan) of arterial pulmonary hypertension, regardless of the functional class, was 1 200 000 rubles. and 1 300 000 rubles. respectively, with the need for 12 and 13 packs of the drug per year. The average annual cost of treatment with bosentan ranges from 1 368 900 rubles. up to 1 471 644 rubles. respectively, with the need for 13 and 14 packs of the drug. The results of the “cost minimization” analysis, carried out on the assumption of equal effectiveness of ambrisentan and bosentan, showed that per one patient for one year, the preparation of Volibris (ambrisentan) in comparison with the preparations of bosentan (Traklir and Bozeneks) 175 760 to 178 504 rubles. The values of the “cost-utility” coefficient for ambrisentan in the treatment of pulmonary arterial hypertension II and III of the functional class varied depending on the dosage (5 or 10 mg) from 1,831,563 rubles. up to 2 012 040 rubles for QALY and 2 667 711 rubles up to 2 787 728 rubles. for QALY. At the same time, similar averaged values for bosentan amounted to 2 480 073 rubles and 3 271 174 rubles for QALY for II and III functional class pulmonary arterial hypertension, respectively. The “budget impact” analysis based on the estimated number of patients with pulmonary arterial hypertension in the Russian Federation, which is 2936 people, showed that the transfer of this number of patients treated with the bosentan in the form of original (Tracler) and reproduced (Bozeneks) 1: 1, for treatment with the drug ambrisentan (Volibris), will allow for 2 years to save 853.2 million rubles, which is 9.7% of the budget required for the treatment of bosentan.

1 | 2